Silence Therapeutics (SLN) Intangibles (2018 - 2026)
Silence Therapeutics recorded quarterly Intangibles of $248000.0 in Q1 2026, down 13.89% quarter-over-quarter from $288000.0 in Q4 2025, and down 20.0% year-over-year from $310000.0 in Q1 2025.
Silence Therapeutics' Intangibles history runs 9 years deep, the most recent figure standing at $248000.0 for Q1 2026.
- In Q1 2026, Intangibles fell 20.0% year-over-year to $248000.0; the TTM figure through Mar 2026 stood at $248000.0 (down 20.0% YoY), while the FY2025 annual figure was $288000.0, down 7.69% from the prior year.
- Intangibles came in at $248000.0 for Q1 2026 at Silence Therapeutics, down from $288000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $377911.7 in Q2 2023 to a low of $23571.0 in Q3 2022.
- A 5-year average of $278272.7 and a median of $317000.0 in 2025 frame the typical range for Intangibles.
- Across the five-year window, Intangibles surged 1474.56% in 2023 and slipped 20.0% in 2026, its largest moves.
- Silence Therapeutics' Intangibles stood at $375337.1 in 2022, then dropped by 6.09% to $352487.1 in 2023, then declined by 11.49% to $312000.0 in 2024, then decreased by 7.69% to $288000.0 in 2025, then slipped by 13.89% to $248000.0 in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $248000.0, $288000.0, and $300000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | 248,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248,000.00 |
| Dec 31, 2025 | 288,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Dec 31, 2024 | 312,000.00 |
| Sep 30, 2024 | 335,219.44 |
| Jun 30, 2024 | 337,012.94 |
| Mar 31, 2024 | 348,842.50 |
| Dec 31, 2023 | 352,487.14 |
| Sep 30, 2023 | 371,138.64 |
| Jun 30, 2023 | 377,911.67 |
| Mar 31, 2023 | 376,807.95 |
| Dec 31, 2022 | 375,337.06 |
| Sep 30, 2022 | 23,570.97 |
| Jun 30, 2022 | 26,445.60 |
| Mar 31, 2022 | 30,862.22 |
| Dec 31, 2021 | 175,241.38 |
| Sep 30, 2021 | 4,135.75 |
| Jun 30, 2021 | 9,784.10 |
| Dec 31, 2020 | 141,288.26 |
| Jun 30, 2020 | 34,767.48 |
| Dec 31, 2019 | 131,143.94 |
| Jun 30, 2019 | 60,456.69 |
| Dec 31, 2018 | 82,353.10 |